Targeted therapy of human osteosarcoma with 17AAG or rapamycin: Characterization of induced apoptosis and inhibition of mTOR and Akt/MAPK/Wnt pathways

International Journal of Oncology

Volumn 34, Issue 2, 2009, Pages 551-561

  Gazitt, Yair ^a   Kolaparthi, Venkatasubbarao ^a   Moncada, Karla ^a   Thomas, Charles ^a   Freeman, James ^a  

^a University of Texas Health Science Center at San Antonio   (United States)

Author keywords

17AAG; Akt mTOR; Apoptosis; Hsp90; Rapamycin; Sarcoma

Indexed keywords

APOPTOSIS INDUCING FACTOR; CASPASE 8; CASPASE 9; CYCLIN D1; CYCLIN DEPENDENT KINASE 1; GLUTATHIONE; GLYCOGEN SYNTHASE KINASE 3BETA; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 34; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45A; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; RAPAMYCIN; TANESPIMYCIN; TUBERIN; UNCLASSIFIED DRUG; WNT PROTEIN;

APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; FEMALE; HUMAN; HUMAN CELL; MEMBRANE DEPOLARIZATION; MITOCHONDRIAL MEMBRANE POTENTIAL; OSTEOSARCOMA; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION;

ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; BENZOQUINONES; BONE NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; HUMANS; LACTAMS, MACROCYCLIC; MITOCHONDRIAL MEMBRANES; OSTEOSARCOMA; PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; SIROLIMUS;

EID: 64549109015     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000181     Document Type: Article

References (53)

1. Brecht IB and Treuner J: Soft tissue sarcoma in children and adolescents: experiences of the cooperative Soft Tissue Sarcoma Group Studies (CWS-81-96). Handchir Mikrochir Plast Chir 36: 275-281, 2004.
2. Jemal A, Murray T, Ward E, et al: Cancer statistics 2005. CA Cancer J Clin 55: 10-30, 2005.
3. O'Bryan RM, Baker LH, Gottlieb JE, et al: Dose response evaluation of adriamycin in human neoplasia. Cancer 39: 1940-1948, 1977.
4. Antman KH, Ryan L, Elias A, et al: Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma. J Clin Oncol 7: 126-131, 1989.
5. Antman K, Crowley J, Balcerzak SP, et al: An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol 11: 1276-1285, 1993.
6. Patel SR, Vadhan-Raj S, Burgess MA, et al: Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas. Am J Clin Oncol 21: 317-321, 1998.
7. Edmonson JH, Ryan LM, Blum RH, et al: Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol 11: 1269-1275, 1993.
8. Verweij J, Lee SM, Ruka W, et al: Randomized phase II study of docetaxel versus doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: a study of the European organization for research and treatment of cancer soft tissue and bone sarcoma group. J Clin Oncol 18: 2081-2086, 2000.
9. Kasper B, Gil T and Awada A: Treatment of patients with advanced soft tissue sarcoma: disappointment or challenge? Curr Opin Oncol 19: 336-340, 2007.
10. Fahn W and Issels RD: Emerging treatments for soft tissue sarcoma of adults. Exp Opin Emerg Drugs 9: 313-343, 2004.
11. Tsai YC, Wu CT and Hong RL: Response of refractory osteosarcoma to thalidomide and celecoxib. Lancet Oncol 6: 997-999, 2005.
12. Balasubramanian L and Evens AM: Targeting angiogenesis for the treatment of sarcoma. Curr Opin Oncol 18: 354-359, 2006.
13. Okuno S: Mammalian target of rapamycin inhibitors in sarcomas. Curr Opin Oncol 18: 360-362, 2006.
14. Martin DE and Hall MN: The expanding TOR signaling network. Curr Opin Cell Biol 17: 158-166, 2005.
15. Sarbassov dos D, Ali SM and Sabatini DM: Growing roles for the mTOR pathway. Curr Opin Cell Biol 17: 596-603, 2005.
16. Vignot S, Faivre S, Aguirre D and Raymond E: mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 16: 525-537, 2005.
17. Inoki K, Corradetti MN and Guan KL: Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet 37: 19-24, 2005.
18. Petroulakis E, Mamane Y, Le Bacquer O, et al: mTOR signaling: implications for cancer and anticancer therapy. Br J Cancer 94: 195-199, 2006,
19. Morgensztern D and McLeod HL: PI3K/Akt/mTOR pathway as a target for cancer therapy. Anticancer Drugs 16: 797-803, 2005.
20. Cohen E: mTOR inhibitors. Clin Adv Hematol Oncol 4: 38-39, 2006.
21. Mita MM, Mita AC, Chu QS, et al: Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. J Clin Oncol 26: 361-367, 2008.
22. Hidalgo M, Buckner JC, Erlichman C, et al: A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer. Clin Cancer Res 12: 5755-5763, 2006.
23. Sreedhar AS and Csermely P: Heat-shock proteins in the regulation of apoptosis: new strategies in tumor therapy: a comprehensive review. Pharmacol Ther 101: 227-257, 2004.
24. Isaacs JS, Xu W and Neckers L: Heat-shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell 3: 213-217, 2003.
25. Hostein I. Robertson D, Di Stefano F, et al: Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis. Cancer Res 61: 4003-4009, 2001.
26. Mosser DC and Morimoto IR: Molecular chaperones and the stress of oncogenesis. Oncogene 23: 2907-2918, 2004.
27. Zylicz M, King FW and Wawrzynow A: Hsp70 interactions with the p53 tumour suppressor protein. EMBO J 20: 4634-4638, 2001.
28. Walerych, D, Kudla, G, Gutkowska M, et al: Hsp90 chaperones wild-type p53 tumor suppressor protein. J Biol Chem 279: 48836-48845, 2004.
29. Müller P, Ceskova P and Vojtesek B: Hsp90 is essential for restoring cellular functions of temperature- sensitive p53 mutant protein but not for stabilization and activation of wild-type p53: implications for cancer therapy. J Biol Chem 280: 6682-6691, 2004.
30. Zhang H and Burrows F: Targeting multiple signal transduction pathways through inhibition of Hsp90. J Mol Med 82: 488-499, 2004.
31. Workman P: Overview: Translating Hsp90 biology into Hsp90 drugs. Curr Cancer Drug Targets 3: 297-300, 2003.
32. Xiao L, Lu X and Ruden DM: Effectiveness of hsp90 inhibitors as anti-cancer drugs. Mini Rev Med Chem 6: 1137-1143, 2006.
33. Drysdale MJ, Brough PA, Massey A, et al: Targeting Hsp90 for the treatment of cancer. Curr Opin Drug Discov Devel 9: 483-495, 2006.
34. Park JW, Yeh MW, Wong MG, et al: The heat-shock protein 90-binding geldanamycin inhibits cancer cell proliferation, down-regulates oncoproteins, and inhibits epidermal growth factor-induced invasion in thyroid cancer cell lines. J Clin Endocrinol Metab 88: 3346-3353, 2003.
35. Solit DB, Zheng FF, Drobnjak M, et al: 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res 8: 986-993, 2002.
36. An WG, Schulte TW and Neckers LM: The heat-shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before their degradation by the proteasome. Cell Growth Differ 11: 355-360, 2000.
37. Dymock BW, Barril X, Brough PA, et al: Novel, potent small-molecule inhibitors of the molecular chaperone Hsp90 discovered through structure-based design. J Med Chem 48: 4212-4215, 2005.
38. Terry J, Lubieniecka JM, Kwan W, et al: Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin prevents synovial sarcoma proliferation via apoptosis in vitro models. Clin Cancer Res 11: 5631-5638, 2005.
39. Ikeda T, Futaesaku Y and Tsuchida N: In vitro differentiation of the human osteosarcoma cell lines, HOS and KHOS. Virchows Arch B Cell Pathol 62: 199-206, 1992.
40. Liu Q, Hilsenbeck S and Gazitt Y: Arsenic trioxide-induced apoptosis in myeloma cells: p53 dependent G1 or G2/M cell cycle arrest, activation of caspase-8 or caspase-9 and synergy with APO2/Trail. Blood 101: 4078-4087, 2003.
41. Akay C, Thomas C and Gazitt Y: Arsenic trioxide and paclitaxel induce apoptosis by different mechanisms. Cell Cycle 3: 324-334, 2004.
42. Hedley DW and Chow S: Evaluation of methods for measuring cellular glutathione content using flow cytometry. Cytometry 15: 349-358, 1994.
43. Akay C and Gazitt Y: Arsenic trioxide selectively induces early and extensive apoptosis via the APO2/caspase-8 pathway engaging the mitochondrial pathway in myeloma cells with mutant p53. Cell Cycle 2: 358-368, 2003.
44. Liu Q and Gazitt Y: Potentiation of dexamethasone,taxol and Ad-p53-induced apoptosis by bcl-2 anti-sense oligodeoxynucleotides in drug-resistant multiple myeloma cells. Blood 101: 4105-4114, 2003.
45. Moon TR, Bowerman B, Boutros M, et al: The promise and perils of Wnt signaling through β-catenin. Science 296: 1644-1647, 2002.
46. Doble BW and Woodgett JR: GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci 116: 1175-1186, 2003.
47. Schmitt E, Gehrmann M, Brunet M, et al: Intracellular and extracellular functions of heat-shock proteins: repercussions in cancer therapy. J Leukoc Biol 81: 15-27, 2007.
48. Lochhead PA, Kinstrie R, Sibbet G, et al: A chaperone-dependent GSK3beta transitional intermediate mediates activation-loop authophosphorylation. Mol Cell 24: 627-633, 2006.
49. Gray PJ Jr, Stevenson MA and Calderwood SK: Targeting Cdc37 inhibits multiple signaling pathways and induces growth arrest in prostate cancer cells. Cancer Res 67: 11942-11950, 2007.
50. Hung WJ, Roberson RS, Taft J, et al: Human BAG-1 proteins bind to the cellular stress response protein GADD34 and interfere with GADD34 functions. Mol Cell Biol 23: 3477-3486, 2003.
51. Hollander MC, Zhan Q, Bae I and Fornace AJ Jr: Mammalian GADD34, an apoptosis- and DNA damage-inducible gene. J Biol Chem 272: 13731-13737, 1997.
52. DeWolf WC and Gaston SM: The cell cycle and its relevance to the urologist. J Urol 171: 1674-1681, 2004.
53. Ramanathan RK, Trump DL, Eiseman JL, et al: Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat-shock protein 90, in patients with refractory advanced cancers. Clin Cancer Res 11: 3385-3391, 2005.